ZBH Quote, Financials, Valuation and Earnings

Haemonetics has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of 9.79%. Zimmer Biomet Holdings's return on equity of 8.63% beat Haemonetics's return on equity of 13.51%.

Zimmer Biomet Holdings has a consensus price target of $123.76, signalling upside risk potential of 15.39%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 40.52%. Given that Haemonetics has higher upside potential than Zimmer Biomet Holdings, analysts believe Haemonetics is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.749%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.8B, which are larger than Haemonetics quarterly revenues of $345.5M. Zimmer Biomet Holdings's net income of $249.1M is higher than Haemonetics's net income of $33.8M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.39x while Haemonetics's PE ratio is 32.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 2.98x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of -211%. Zimmer Biomet Holdings's return on equity of 8.63% beat Nutriband's return on equity of -69.58%.

Zimmer Biomet Holdings has a consensus price target of $123.76, signalling upside risk potential of 15.39%. On the other hand Nutriband has an analysts' consensus of -- which suggests that it could grow by 355.7%. Given that Nutriband has higher upside potential than Zimmer Biomet Holdings, analysts believe Nutriband is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison Nutriband has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.193%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.8B, which are larger than Nutriband quarterly revenues of $645.8K. Zimmer Biomet Holdings's net income of $249.1M is higher than Nutriband's net income of -$1.4M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.39x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 19.36x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of 25.43%. Zimmer Biomet Holdings's return on equity of 8.63% beat ResMed's return on equity of 23.76%.

Zimmer Biomet Holdings has a consensus price target of $123.76, signalling upside risk potential of 15.39%. On the other hand ResMed has an analysts' consensus of $206.05 which suggests that it could grow by 8.22%. Given that Zimmer Biomet Holdings has higher upside potential than ResMed, analysts believe Zimmer Biomet Holdings is more attractive than ResMed.

Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison ResMed has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.593%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.8B, which are larger than ResMed quarterly revenues of $1.2B. Zimmer Biomet Holdings's net income of $249.1M is lower than ResMed's net income of $311.4M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.39x while ResMed's PE ratio is 30.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 7.18x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 13.66% compared to Zimmer Biomet Holdings's net margin of 15.18%. Zimmer Biomet Holdings's return on equity of 8.63% beat Stryker's return on equity of 18.78%.

Zimmer Biomet Holdings has a consensus price target of $123.76, signalling upside risk potential of 15.39%. On the other hand Stryker has an analysts' consensus of $406.60 which suggests that it could grow by 10.06%. Given that Zimmer Biomet Holdings has higher upside potential than Stryker, analysts believe Zimmer Biomet Holdings is more attractive than Stryker.

Zimmer Biomet Holdings has a beta of 1.017, which suggesting that the stock is 1.712% more volatile than S&P 500. In comparison Stryker has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.217%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 0.9%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.80 per share. Zimmer Biomet Holdings pays 19.62% of its earnings as a dividend. Stryker pays out 35.99% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.8B, which are smaller than Stryker quarterly revenues of $5.5B. Zimmer Biomet Holdings's net income of $249.1M is lower than Stryker's net income of $834M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.39x while Stryker's PE ratio is 39.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.91x versus 6.47x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.